Skip to main content
MMedVellum
MCQsExamsAtlas
DashboardPricing
MMedVellum

The exam atlas that feels like a flagship product — evidence-graded topics and exam tools for MBBS and fellowship preparation. Built to scale to fifty specialties. Educational content only — not medical advice.

llms.txt·psychiatry LLM catalog · sitemap

Atlas

  • Specialty atlas
  • MBBS / Core medicine
  • Dermatology
  • ICU Fellowship (CICM)
  • Anaesthesia
  • Emergency Medicine
  • Psychiatry Fellowship

Study & account

  • MCQ practice
  • Practice alias
  • Exam tools
  • Dashboard
  • Pricing
  • Sign in

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

Clinical Atlas Prestige · Evidence-first

Psych MEQs / SAQsSpecialty psychiatry — sleep medicine interface

Psych MEQs / SAQs · Specialty psychiatry — sleep medicine interface

Chronic insomnia with depression and hypnotic dependence (MEQ)

FRANZCP-style MEQ on chronic insomnia: CBT-I first-line, hypnotic dependence, OSA screen, occupational sleepiness, depression bidirectional risk. FRANZCP-primary, globally tagged.

20 marks20 min
On this page & tools

Target exams

FRANZCPMRCPsychABPNMD-DNB

Target exams

FRANZCPMRCPsychABPNMD-DNB
Prompt
A 48-year-old woman with recurrent MDD reports 4 years of sleep-onset and maintenance insomnia (≥5 nights/week), ISI in the moderate–severe range, and daytime fatigue. She drinks two glasses of wine most nights 'to switch off,' uses zopiclone most nights for 18 months, and has had three antidepressant trials with residual insomnia. BMI 34 kg/m²; partner reports loud snoring. PHQ-9 remains 14. She drives a forklift and had one near-miss after nodding off at work. (i) Formulate the sleep diagnoses and key differentials. (ii) Outline assessment and investigations. (iii) Propose a stepped non-drug and drug plan including CBT-I and hypnotic deprescribing. (iv) Address OSA and occupational risk. (v) Link insomnia to depression/suicide risk with evidence. (20 marks)

Model answer

Reveal model answer

(i) Formulation. Chronic insomnia disorder (sleep onset and maintenance, frequency and multi-year course, daytime impairment) comorbid with residual MDD. Contributing/maintaining factors: alcohol (shortens latency but fragments architecture), long-term zopiclone with likely tolerance/dependence pattern, possible OSA (BMI, snoring). Differentials: primary vs comorbid insomnia (both treated), circadian delay less likely given description, RLS not described, medical pain/thyroid not yet excluded, substance-induced sleep disorder component from alcohol/hypnotic.[1][4][7]

(ii) Assessment/investigations. Structured sleep history and 1–2 week diary; substances; suicide risk; driving/occupational sleepiness (near-miss is a red flag). Partner history for apnoeas. ISI/ESS as clinical tools. Screen OSA (STOP-BANG-type factors). Review medications. Consider sleep study given high OSA probability; not required to start CBT-I for typical insomnia features but should not delay OSA pathway. Baseline mood scales; medical labs as indicated (TFT, FBC, glucose, etc.).[4][1]

(iii) Stepped plan. Psychoeducation; stop using alcohol as hypnotic. CBT-I first-line (stimulus control, sleep restriction with occupational safety planning, cognitive therapy, relaxation, education) — face-to-face or digital depending on access; evidence for clinically meaningful benefit.[1][2][3][7] Optimise depression treatment in parallel (not instead of CBT-I). Hypnotic deprescribing: shared plan to taper zopiclone (slow taper if dependence features), avoid dose escalation, do not replace with open-ended quetiapine for primary insomnia. Short-term bridge only if needed during CBT-I initiation with exit criteria. Sedating antidepressant choices only if depression warrants, knowing hangover/OSA weight risks.[1][7]

(iv) OSA and work. Refer sleep medicine; weight management; alcohol reduction. Pending assessment, discuss temporary work safety (no forklift if sleepy), employer/OHS liaison as appropriate, legal fitness-to-drive/operate machinery principles by jurisdiction. CPAP if moderate–severe OSA confirmed — support adherence.[4]

(v) Depression/suicide evidence. Longitudinal meta-analysis shows insomnia predicts incident depression; sleep disturbance associates with suicidal ideation/attempt/death — document SI carefully and treat sleep as part of risk reduction, not optional comfort care.[5][6]

Common errors

  • Only increasing zopiclone dose.
  • Ignoring OSA and alcohol.
  • Claiming CBT-I is “optional lifestyle advice.”
  • Discharging without occupational near-miss plan.
  • Treating insomnia as purely secondary and waiting for mood to remiss fully before any sleep treatment. [1][2][6]

Examiner notes

Award marks for simultaneous CBT-I + depression optimisation + OSA pathway + deprescribing + risk. Full marks require evidence-linked first-line CBT-I (ACP/AASM/Europe) and suicide/depression bidirectionality. [1][2][5]

References

  1. [1]Qaseem A, Kansagara D, Forciea MA, et al. Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians Ann Intern Med, 2016.PMID 27136449
  2. [2]Edinger JD, Arnedt JT, Bertisch SM, et al. Behavioral and psychological treatments for chronic insomnia disorder in adults: an American Academy of Sleep Medicine clinical practice guideline J Clin Sleep Med, 2021.PMID 33164742
  3. [3]Trauer JM, Qian MY, Doyle JS, et al. Cognitive Behavioral Therapy for Chronic Insomnia: A Systematic Review and Meta-analysis Ann Intern Med, 2015.PMID 26054060
  4. [4]Peppard PE, Young T, Barnet JH, et al. Increased prevalence of sleep-disordered breathing in adults Am J Epidemiol, 2013.PMID 23589584
  5. [5]Baglioni C, Battagliese G, Feige B, et al. Insomnia as a predictor of depression: a meta-analytic evaluation of longitudinal epidemiological studies J Affect Disord, 2011.PMID 21300408
  6. [6]Pigeon WR, Pinquart M, Conner K Meta-analysis of sleep disturbance and suicidal thoughts and behaviors J Clin Psychiatry, 2012.PMID 23059158
  7. [7]Riemann D, Baglioni C, Bassetti C, et al. European guideline for the diagnosis and treatment of insomnia J Sleep Res, 2017.PMID 28875581
  8. [8]Glass J, Lanctot KL, Herrmann N, et al. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits BMJ, 2005.PMID 16284208